Abivax Stock (EPA: ABVX) at 77.55 EUR, down 30.64% as Safety Signals Cloud Colitis Trial Results

Abivax Stock came under heavy pressure on June 2, 2026, after investors focused on safety concerns linked to its ulcerative colitis drug candidate, obefazimod. The stock fell 30.64% to 77.55 EUR even though the company reported stronger-than-expected Phase 3 trial results. The sharp selloff shows that safety signals can outweigh positive efficacy data in biotechnology stocks. 

Abivax Stock Falls Despite Strong Clinical Results

• Clinical remission exceeded expectations

Remission rates reached 50.8% for the 25 mg dose and 51.3% for the 50 mg dose after 44 weeks, compared with only 10.4% for placebo among 580 patients enrolled in the ABTECT maintenance study.

• Placebo-adjusted efficacy stood out

The placebo-adjusted remission rates were 39.3% for 25 mg and 40.3% for 50 mg, levels that analysts described as among the strongest seen in a large Phase 3 ulcerative colitis trial. 

• Why did the market react negatively?

Several malignancy cases appeared in the higher dose arm, including prostate cancer, breast cancer, and colon cancer, each representing roughly 0.5% incidence. Investigators stated that the cases were not linked to the treatment, but investors remained cautious. 

Abivax Stock and the Safety Questions Investors Are Asking

1. Were new safety signals reported?

Treatment-related adverse events occurred in 71.8% of patients on 50 mg, 58.0% on 25 mg, and 50.0% on placebo. No deaths were reported, and serious infections remained below 1% across groups. 

2. Is FDA approval still on track?

Abivax plans to submit its New Drug Application to the FDA in Q4 2026. Management continues to describe obefazimod’s overall benefit-risk profile as favorable. 

3. What are analysts saying?

Analysts from firms including Stifel and Leerink Partners noted that efficacy results were well above expectations. However, the malignancy findings created uncertainty around future labeling and regulatory review. Coverage by CNBC highlighted the market’s concern over safety perception despite strong data. 

Abivax Stock Valuation Outlook and Market Implications

• Previous bullish targets remain under review

Before the trial release, some analysts had price targets near $131 per share on the NASDAQ-listed stock. Following the 30% plus decline, investors are reassessing regulatory risk and commercial potential. 

• Financial position remains solid

Abivax reported approximately €491.6 million in cash and short-term investments at the end of the first quarter of 2026, providing an expected runway into Q4 2027. 

MEYKA Analyst Review On Abivax Stock

The reaction in Abivax Stock reflects a classic biotechnology market response. Investors generally reward strong efficacy, but they often punish uncertainty around safety. On one side, obefazimod delivered clinical remission above 50%, met all key endpoints, and produced placebo-adjusted benefits exceeding 39%. On the other hand, the appearance of several cancer cases in the higher dose group raised questions that the market could not ignore.

Current evidence does not establish a causal relationship between the drug and the malignancies, according to investigators. However, institutional investors are likely waiting for additional regulatory feedback before assigning full value to the program. With an FDA filing planned for Q4 2026, future updates could become major catalysts. 

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.